← Leaderboards
Robert Paul Myers
Orsobio, Inc.
$1,149,999
Attributed
$2,299,997
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1000K · FY2022–24$1M$750K$500K$250K$0
'22
'23
'24
Funding mix
By agency
NIH$2,299,997 · 1
By mechanism
R44$2,299,997 · 1
Top collaborators
- Archana Vijayakumar3 shared
Others in their field
Other Rising Stars on “Achievement”
- Mari Ostendorf · University Of Washington$51,931,230
- Nancy Jean Sullivan · Boston University Medical Campus$34,500,000
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Cathie Snyder · Rho Federal Systems Division, Inc.$13,500,724
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
- Jaymi L Smith · University Of California-Irvine$10,664,283
Research focus
AchievementEnergy MetabolismAdverse EffectsAnimal Disease Models2,4-DinitrophenolAdenosine TriphosphateBiologicalBody Weight DecreasedCanis FamiliarisCell MembraneClinical ResearchAnimalsControlled ReleaseDiabetes MellitusDiglyceridesDinitrophenolsDoseDrug InteractionsDrug KineticsDrug MetabolismDyslipidemiasEffective TherapyElectron TransportExhibits
Grant awards (3)
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy$999,999
R44 · FY2024 · DK · contact PI
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy$999,999
R44 · FY2023 · DK · contact PI
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy$299,999
R44 · FY2022 · DK · contact PI